
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
IMV Inc. ("IMV" or the "Company") IMVIMV, a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that on March 29, 2023, IMV …